Home / Sponsors

Your protocol,
run right.

Veritas Clinical Research is a physician-led pulmonary site in Madison Heights, Michigan — a single PI, a dedicated coordinator team, and a portfolio that spans asthma, COPD, IPF, and bronchiectasis from Phase II to Phase IV.

13Trials as PI site
4Therapeutic areas
II–IVPhase experience
§ 01 / Track record

Every trial. On the record.

1 recruiting · 5 active · verifiable on ClinicalTrials.gov
NCT
Study
Phase / Indication
Status
NCT07190209

Lunsekimig vs. placebo in inadequately controlled eosinophilic COPD

Phase III · COPD
Recruiting
NCT06748053

Dose-finding study of an anti-TSLP antibody (GSK5784283) in uncontrolled asthma

Phase II · Asthma
Active · not recruiting
NCT05748600

Dexpramipexole in adolescents and adults with eosinophilic asthma

Phase III · Asthma
Active · not recruiting
NCT06208306

Long-term safety and tolerability of itepekimab in COPD

Phase III · COPD
Active · not recruiting
NCT03953300

Benralizumab airway remodeling study in severe eosinophilic asthma

Phase IV · Asthma
Active · not recruiting
NCT06372496

FF/UMEC/VI vs. non-Ellipta usual-care ICS-LABA in uncontrolled asthma

Phase IV · Asthma
Active · not recruiting
NCT04718389

Depemokimab (GSK3511294) vs. mepolizumab or benralizumab in severe eosinophilic asthma

Phase III · Asthma
Completed
NCT04701983

Efficacy, safety, and tolerability of itepekimab (SAR440340/REGN3500) in COPD

Phase III · COPD
Completed
NCT05326412

Mechanistic study of itepekimab on airway inflammation in COPD

Phase II · COPD
Completed
NCT06335303

BI 1819479 for improvement of lung function in idiopathic pulmonary fibrosis (IPF)

Phase II · IPF
Completed
NCT06280391

Itepekimab (anti-IL-33 mAb) proof-of-concept in non-cystic-fibrosis bronchiectasis

Phase II · Bronchiectasis
Completed
NCT05813288

Dexpramipexole in adolescents and adults with severe eosinophilic asthma (EXHALE-3)

Phase III · Asthma
Terminated
NCT06360094

BI 1839100 for cough in idiopathic or progressive pulmonary fibrosis

Phase II · IPF / PPF
Terminated
§ 02 / Capabilities

Built for pulmonary protocols.

4,200 sq ft · 8 FTE · Madison Heights, MI
Pulmonary testing
Full PFT laboratory

Spirometry · lung volumes · DLCO · 6-minute walk · FeNO

Calibrated daily, NBRC-certified technologist
Imaging
HRCT + chest radiography

Via partner imaging center · 1.2 mi from site

Same-day scheduling, secure sponsor transfer
Specimen
IATA-certified specimen handling

Central lab processing · on-site -80°C freezer · courier chain

Sponsor-qualified for oncology-grade chain of custody
Systems
EDC · CTMS · eSource-ready

Veeva · Medidata Rave · Oracle Siebel — compatible

Part 11 compliant, typical activation 28 days
Regulatory
Full IRB submission infrastructure

Central + local IRB workflows · 1572/FDF on file

Zero critical findings last 3 audits
§ 03 / Working with us

What sponsors get.

PI-led · GCP · FDA-inspected
◈ Feasibility

The PI on every feasibility call

Dr. Parodi reviews every protocol personally — enrollment projections come from the physician who will actually screen the patients, not from a business development deck.

◈ Coordination

One coordinator, start to finish

A single named coordinator owns your study — monitoring visits, queries, and IRB traffic move through one person who knows the protocol cold.

◈ Transparency

Metrics you can audit

Screening, enrollment, and retention numbers reported as they are — the same radical transparency we promise participants applies to sponsors.

◈ Site qualification

One request gets you everything.

Regulatory packet, capability statement, and metrics dashboard — request all three through the contact form, or call us at (586) 210-0330.